AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36053806 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg and 800 mg
Number of subjects: 0
Study 36053806 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration with food
Number of subjects: 0
Study 34290036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-delivered CV educational videos and CPR video
Number of subjects: 330
Study 34290036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-delivered CV educational videos
Number of subjects: 330
Study 34290036 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR video
Number of subjects: 330
Study 34290036 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline to 30-day follow-up CV RFs
Number of subjects: 330
Study 34290036 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study 36418441 — intervention group
Group type: EXPERIMENTAL
Intervention: Music training (piano training)
Number of subjects: 31
Study 36418441 — intervention group
Group type: COMPARATOR
Intervention: Music listening
Number of subjects: 31
Study 36418441 — intervention group
Group type: COMPARATOR
Intervention: Control group (doing homework)
Number of subjects: 31
Study 32047237 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD-haplo + ATIR101
Number of subjects: 23
Study 32047237 — intervention group
Group type: COMPARATOR
Intervention: TCD-haplo alone
Number of subjects: 23
Study 32047237 — intervention group
Group type: COMPARATOR
Intervention: MMUD
Number of subjects: 23
Study 32047237 — intervention group
Group type: COMPARATOR
Intervention: MUD
Number of subjects: 23
Study 32047237 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIR101 grafts with high third-party reactivity
Number of subjects: 23
Study 34999928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-diet (n-6 PUFA)
Number of subjects: 99
Study 34999928 — intervention group
Group type: COMPARATOR
Intervention: C-diet (Control)
Number of subjects: 99
Study 32359044 — intervention group
Group type: EXPERIMENTAL
Intervention: Group behavioral couples' therapy plus individual‐based treatment (G‐BCT)
Number of subjects: 101
Study 32359044 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral couples' therapy plus individual‐based treatment (S‐BCT)
Number of subjects: 101
Study 32359044 — intervention group
Group type: COMPARATOR
Intervention: Incremental cost-effectiveness ratios (ICER) moving from G‐BCT to S‐BCT
Number of subjects: 101
Study 32359044 — intervention group
Group type: COMPARATOR
Intervention: Percentage days abstinent, adverse consequences of alcohol and drugs, overall relationship functioning
Number of subjects: 101
Study 34998419 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 260
Study 34998419 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab RP
Number of subjects: 260
Study 35676457 — intervention group
Group type: EXPERIMENTAL
Intervention: LSDL (Laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation)
Number of subjects: 88
Study 35676457 — intervention group
Group type: EXPERIMENTAL
Intervention: LSDL
Number of subjects: 88
Study 35676457 — intervention group
Group type: COMPARATOR
Intervention: LSD (Laparoscopic splenectomy and azygoportal disconnection)
Number of subjects: 88
Study 33851461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2 g)
Number of subjects: 60
Study 33851461 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 60
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: EBNA1-IgA
Number of subjects: 106
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV DNA
Number of subjects: 106
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: VCA-IgA
Number of subjects: 106
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-IgA
Number of subjects: 106
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: Rta-IgG
Number of subjects: 106
Study 32780356 — intervention group
Group type: EXPERIMENTAL
Intervention: Zta-IgA
Number of subjects: 106
Study 32780356 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 106
Study 33497362 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine
Number of subjects: 22
Study 33625518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Timolol
Number of subjects: 3
Study 33625518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 34437553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (various attributes assessed)
Number of subjects: 506
Study 34437553 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-drug interaction concern
Number of subjects: 506
Study 34437553 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of blood monitoring
Number of subjects: 506
Study 34437553 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment and income level impact
Number of subjects: 506
Study 32511774 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberalized dietary sodium intake (200 mmol/d, 4600 mg/d)
Number of subjects: 630
Study 32511774 — intervention group
Group type: COMPARATOR
Intervention: Restricted dietary sodium intake (10 mmol/d, 230 mg/d)
Number of subjects: 630
Study 34338327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization using genetic variants as instruments
Number of subjects: 0
Study 34338327 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sample conditional F-statistic
Number of subjects: 0
Study 34338327 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneity Q-statistic
Number of subjects: 0
Study 36343090 — intervention group
Group type: EXPERIMENTAL
Intervention: NERD stagnated heat in liver and stomach syndrome group
Number of subjects: 60
Study 36343090 — intervention group
Group type: COMPARATOR
Intervention: qi stagnation and phlegm obstruction syndrome control group
Number of subjects: 60
Study 36343090 — intervention group
Group type: COMPARATOR
Intervention: normal control group
Number of subjects: 60
Study 35192610 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP 2.0 to 4.9 mg/L
Number of subjects: 102337
Study 35192610 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP 5 to 9.9 mg/L
Number of subjects: 102337
Study 35192610 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP 10 to 15 mg/L
Number of subjects: 102337
Study 35192610 — intervention group
Group type: COMPARATOR
Intervention: hsCRP <2 mg/L
Number of subjects: 102337
Study 34287833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 20 mg/kg/day, titrated up to 30 mg/kg/day over 2 weeks
Number of subjects: 366
Study 34287833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment
Number of subjects: 366
Study 32846328 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 22678
Study 32846328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22678
Study 36342337 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about health, medication use, and communication strategies
Number of subjects: 0
Study 36342337 — intervention group
Group type: COMPARATOR
Intervention: Traditional services (control group)
Number of subjects: 0
Study 33561565 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based interventions
Number of subjects: 9
Study 32540210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory accreditation (non-monetary incentive)
Number of subjects: 846
Study 32540210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of accreditation as a tool for external control
Number of subjects: 846
Study 32859731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-Propofol (KP)
Number of subjects: 96
Study 32859731 — intervention group
Group type: COMPARATOR
Intervention: Sodium Thiopental-Fentanyl (TF)
Number of subjects: 96
Study 34928708 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125
Study 34928708 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1125
Study 32077768 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention
Number of subjects: 87
Study 32077768 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 87
Study 36146287 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time wearable feedback with daily goal using the Manumeter device for three weeks
Number of subjects: 20
Study 36146287 — intervention group
Group type: COMPARATOR
Intervention: Control group using the Manumeter as a wristwatch without real-time feedback for three weeks
Number of subjects: 20
Study 33226425 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/d ezogabine
Number of subjects: 65
Study 33226425 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d ezogabine
Number of subjects: 65
Study 33226425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 35090543 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restriction training (BFRT)
Number of subjects: 78
Study 35090543 — intervention group
Group type: COMPARATOR
Intervention: Sham BFRT
Number of subjects: 78
Study 35090543 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care physical therapy
Number of subjects: 78
Study 34137474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 90
Study 34137474 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss (BWL)
Number of subjects: 90
Study 32799922 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity speed‐based treadmill training (HISTT)
Number of subjects: 81
Study 32799922 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS+AMT (15 min of concurrent tDCS and ankle motor tracking)
Number of subjects: 81
Study 32799922 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (15 min of stimulation‐based priming)
Number of subjects: 81
Study 32799922 — intervention group
Group type: COMPARATOR
Intervention: Control (15 min of rest)
Number of subjects: 81
Study 32799922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle motor tracking (AMT) with sham tDCS (15 min of movement‐based priming)
Number of subjects: 81
Study 36817806 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive training program including teaching parental roles and supportive methods, nurse counseling and support role performed virtually
Number of subjects: 40
Study 36817806 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study 32482668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored therapeutic exercise protocol followed by a cryotherapy session of 20 min
Number of subjects: 0
Study 32482668 — intervention group
Group type: COMPARATOR
Intervention: Sham control group receiving the same regimen as the experimental group but with sham packs filled with dry sand
Number of subjects: 0
Study 32482668 — intervention group
Group type: COMPARATOR
Intervention: Active treatment control group receiving only the therapeutic exercise protocol
Number of subjects: 0
Study 35534916 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐6‐PD‐deficient RBCs
Number of subjects: 24
Study 35534916 — intervention group
Group type: COMPARATOR
Intervention: Normal RBCs
Number of subjects: 24
Study 32223002 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride 4% with epinephrine 1:100,000
Number of subjects: 184
Study 32223002 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride 2% with epinephrine 1:100,000
Number of subjects: 184
Study 36305963 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing B. lactis HN019
Number of subjects: 60
Study 36305963 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 60
Study 34274619 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth followup with wearable sensors
Number of subjects: 0
Study 34274619 — intervention group
Group type: COMPARATOR
Intervention: Traditional face to face visits with symptom diaries
Number of subjects: 0
Study 35830578 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 48
Study 35830578 — intervention group
Group type: COMPARATOR
Intervention: In-person visits
Number of subjects: 48
Study 34756733 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D miniplate osteosynthesis
Number of subjects: 2
Study 34756733 — intervention group
Group type: COMPARATOR
Intervention: Two Champy's miniplates
Number of subjects: 2
Study 34748679 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 82
Study 34748679 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 82
Study 33515070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (7.5 mg with dose escalation to 67.5 mg)
Number of subjects: 44
Study 33515070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 33515070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (in children with the type 1 diabetes‐susceptible INS genotype)
Number of subjects: 44
Study 33515070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in children with the type 1 diabetes‐susceptible INS genotype)
Number of subjects: 44
Study 35064428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vermont Family Based Approach (health promotion program)
Number of subjects: 93
Study 33620895 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U onabotulinumtoxinA
Number of subjects: 307
Study 33620895 — intervention group
Group type: COMPARATOR
Intervention: 200 U onabotulinumtoxinA
Number of subjects: 307
Study 32778150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cys/Metlow + PUFA (meal low in sulfur amino acids and high in polyunsaturated fatty acids)
Number of subjects: 10
Study 32778150 — intervention group
Group type: COMPARATOR
Intervention: Cys/Methigh + SFA (meal high in sulfur amino acids and saturated fatty acids)
Number of subjects: 10
Study 36273202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 80 mg + 0.9% normal saline (72 ml) in patient-controlled analgesia pump
Number of subjects: 0
Study 36273202 — intervention group
Group type: COMPARATOR
Intervention: Morphine 80 mg
Number of subjects: 0
Study 32736963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) - 30 breaths at 30–40% of PImax, 5 days a week for 8 weeks
Number of subjects: 12
Study 32736963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 12
Study 32736963 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 32736963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 35193608 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC combined with RTS,S/AS01E
Number of subjects: 5920
Study 35193608 — intervention group
Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 5920
Study 35193608 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01E alone
Number of subjects: 5920
Study 34903244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy using CryoPop®
Number of subjects: 0
Study 35816723 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress
Number of subjects: 16
Study 35816723 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 16
Study 33911153 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell resistance exercise (75% 1RM, 5 repetitions, 3 sets, 2-3 min rest)
Number of subjects: 24
Study 33911153 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell resistance exercise
Number of subjects: 24
Study 33911153 — intervention group
Group type: COMPARATOR
Intervention: Active control (stretching exercise session)
Number of subjects: 24
Study 36482412 — intervention group
Group type: EXPERIMENTAL
Intervention: lecanemab (ED90)
Number of subjects: 856
Study 33992277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates group (PG)
Number of subjects: 46
Study 33992277 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise group (GEG)
Number of subjects: 46
Study 33992277 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group (EG)
Number of subjects: 46
Study 33992277 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 46
Study 33167921 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-oriented proprioceptive antiedema therapy (TAPA)
Number of subjects: 64
Study 33167921 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (Decongestive Lymphedema Therapy (DLT) or Complex Physical Therapy (CPT))
Number of subjects: 64
Study 34649730 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation plus Total Hip Arthroplasty (ORIF + THA)
Number of subjects: 47
Study 34649730 — intervention group
Group type: COMPARATOR
Intervention: Open Reduction and Internal Fixation (ORIF) alone
Number of subjects: 47
Study 32633571 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 1 (coercive tactic first)
Number of subjects: 1253
Study 32633571 — intervention group
Group type: COMPARATOR
Intervention: Version 2 (sexual acts first)
Number of subjects: 1253
Study 35101539 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ‐23 Overall Summary Score (OSS)
Number of subjects: 631
Study 35101539 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ‐23 Clinical Summary Score
Number of subjects: 631
Study 35101539 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ5D‐VAS
Number of subjects: 631
Study 35101539 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class
Number of subjects: 631
Study 33264825 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5734
Study 33264825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5734
Study 32840417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once per day
Number of subjects: 120
Study 32840417 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles)
Number of subjects: 120
Study 32840417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 120
Study 32840417 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 120
Study 32840417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib and Doxorubicin
Number of subjects: 120
Study 35120566 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 50 mg orally, followed by 50 mg once a day for 5 days
Number of subjects: 73
Study 35120566 — intervention group
Group type: COMPARATOR
Intervention: Placebo with the same schedule as minocycline
Number of subjects: 73
Study 36052134 — intervention group
Group type: EXPERIMENTAL
Intervention: SanHanHuaShi granules
Number of subjects: 240
Study 36052134 — intervention group
Group type: COMPARATOR
Intervention: LianHuaQingWen granules
Number of subjects: 240
Study 32493468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon‐β 1a (Recigen)
Number of subjects: 60
Study 32493468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra) + Interferon‐β 1b (Ziferon)
Number of subjects: 60
Study 32493468 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine + Lopinavir / Ritonavir (Kaletra)
Number of subjects: 60
Study 34728529 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 300
Study 34728529 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 32133487 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline 100 mg twice daily for 4 weeks
Number of subjects: 210
Study 32133487 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g daily for 3 weeks
Number of subjects: 210
Study 32242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Content-tailored condition
Number of subjects: 273
Study 32242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Message frame-tailoring
Number of subjects: 273
Study 32242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Content-tailoring
Number of subjects: 273
Study 32242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Message frame-tailoring and content-tailoring interaction
Number of subjects: 273
Study 32242826 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 273
Study 32242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Message frame-tailored for individuals with high need for autonomy + content-tailored messages
Number of subjects: 273
Study 35377557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behavioral Therapy (TCBT) during eight sessions provided by trained general health service providers
Number of subjects: 520
Study 35377557 — intervention group
Group type: COMPARATOR
Intervention: Mental Health Services as Usual (MHSU)
Number of subjects: 520
Study 35437030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 treatment sessions over 4 weeks)
Number of subjects: 0
Study 35437030 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (12 treatment sessions over 4 weeks)
Number of subjects: 0
Study 35437030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 35437030 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 32641335 — intervention group
Group type: EXPERIMENTAL
Intervention: New ultrafiltration (UF) profile with an ascending/descending shape and standard dialysate sodium concentration
Number of subjects: 27
Study 32641335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of different UF and sodium profiling strategies through individualised dialysate sodium concentration
Number of subjects: 27
Study 35400288 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosecond 532 nm laser (PS 532)
Number of subjects: 18
Study 35400288 — intervention group
Group type: COMPARATOR
Intervention: Q-switched 755 nm Alexandrite laser (QSAL)
Number of subjects: 18
Study 32588968 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR with third generation THV systems (Edwards Sapien3®/Sapien3ultra® or Medtronic Evolut‐R®/Evolut‐PRO®) using PerClose‐ProGlide® vascular closure device
Number of subjects: 878
Study 32588968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheath-to-femoral-artery-ratio (SFAR) increase
Number of subjects: 878